Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Glenn Russo

Orthopaedic Surgery Hamden, CT Medical Doctor

NPI 1134488331 CMS profile 3109359

2408 Whitney Ave, Hamden, CT 06518

Open in the dashboard

General payments

$40,752

173 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Glenn Russo of Hamden, CT is reported in the CMS Open Payments database as having received $40,752 across 173 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,642 6
2024 General $11,562 15
2023 General $3,931 18
2022 General $1,711 24
2021 General $14,229 71
2020 General $727 13
2019 General $2,950 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Glenn Russo
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Glenn Russo were reported at $5,642. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Glenn Russo Orthopaedic Surgery median Middle half National median
2019 $2,950 $644 $140–$2,844 $163
2020 $727 $312 $75–$1,860 $114
2021 $14,229 $520 $117–$2,495 $132
2022 $1,711 $598 $128–$2,731 $149
2023 $3,931 $461 $128–$2,264 $160
2024 $11,562 $497 $134–$2,475 $164
2025 $5,642 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Orthofix Medical, Inc. $11,500 9 payments
  2. DePuy Synthes Products, Inc. $8,010 6 payments
  3. Stryker Corporation $7,998 49 payments
  4. Hyhte Holdings Inc. $5,166 1 payment
  5. 4WEB, Inc. $2,200 2 payments
  6. DePuy Synthes Sales Inc. $2,115 53 payments
  7. Medtronic USA, Inc. $2,017 11 payments
  8. SI-BONE, Inc. $571 6 payments
  9. Seaspine Orthopedics Corporation $331 2 payments
  10. Globus Medical, Inc. $195 2 payments
  11. Other $648 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $24,274 6 payments
  2. Food and Beverage $9,135 159 payments
  3. Royalty or License $5,166 1 payment
  4. Travel and Lodging $2,177 7 payments
Products named General payments · program years 2019–2025
  1. Mariner Deformity $10,965 3 payments
  2. Masada MIS, Reunion $5,166 1 payment
  3. CAPRI CORPECTOMY CAGE SYSTEM $4,312 6 payments
  4. SPINE TRUSS SYSTEM $2,200 2 payments
  5. CD HORIZON $1,842 9 payments
  6. AIRO $687 3 payments
  7. CASCADIA INTERBODY SYSTEM $652 6 payments
  8. EVEREST SPINAL SYSTEM $489 6 payments
  9. FIBERGRAFT BG Morsels $383 7 payments
  10. FIBERGRAFT Aeridyan Matrix $370 4 payments
  11. Other $5,508 121 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

385

Median for Orthopedic Surgery: 203

Drug cost

$2,123

Median for Orthopedic Surgery: $1,433

Branded share of claims

3.6%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 55 $537
Methylprednisolone Generic 70 $468
Cyclobenzaprine Hcl Generic 62 $331
Meloxicam Generic 66 $203
Oxycodone Hcl Generic 27 $159
Prednisone Generic 58 $148
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 14 $106
Tramadol Hcl Generic 18 $85
Methocarbamol Generic 15 $85

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$158,669

Of which drugs: $66

Medicare patients

283

Average age 75

Services billed

1,009

171 women, 112 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 31%
Ischemic heart disease 30%
Diabetes 27%
Chronic kidney disease 19%
Osteoporosis 18%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 17 49 $5

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

173 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record